About this Research Topic
Epigenetic modifications and regulators have been shown to undergo significant changes in almost all complex human diseases, including cancers, autoimmune disorders, and psychological conditions. Since the discovery of epigenetic abnormalities in the early stages of these diseases, they have emerged as the most promising biomarkers for diagnosis and prognosis. Notably, epigenetic changes are inheritable and reversible, making them excellent targets for pharmacotherapy and real-time disease surveillance.
In the context of cancer, epigenetic alterations play a crucial role in the development of drug resistance. These modifications can influence the expression of genes involved in drug metabolism, cellular repair mechanisms, and apoptosis, thereby enabling cancer cells to survive and proliferate despite treatment.
Recently, advanced epigenetic sequencing and detection techniques have been developed to analyze DNA and RNA methylation (m5C, 5hmC, m6A), histone modifications (H4K16ac, H3K9me3, H3K27me3, etc.), and non-coding RNAs (miRNA, circRNA, lncRNA, ceRNA, etc.). These technologies provide valuable opportunities for identifying biomarkers that can predict drug resistance and guide the development of novel therapeutic strategies to overcome it.
By leveraging these advancements, we can enhance our understanding of the epigenetic mechanisms underlying cancer drug resistance, paving the way for more effective treatments and improved patient outcomes.
Overall, genomic epigenetic regulation significantly impacts tumor growth, metastasis, and drug resistance. Future studies are essential to deeply explore the relationship between genomic epigenetic regulation and tumor drug resistance, aiming to develop more effective strategies for cancer treatment and prevention.
We invite submissions of original research and review articles on, but not limited to, the following topics:
• Mechanisms of epigenetic regulation in drug-resistant tumors
• Influence of DNA methylation, histone modification, and non-coding RNAs on cancer drug resistance
• Epigenetic biomarkers for predicting and monitoring drug resistance
• Novel epigenetic therapies to overcome drug resistance
• Case studies and clinical trials focused on epigenetic interventions in drug-resistant cancers
In the context of cancer, epigenetic alterations play a crucial role in the development of drug resistance. These modifications can influence the expression of genes involved in drug metabolism, cellular repair mechanisms, and apoptosis, thereby enabling cancer cells to survive and proliferate despite treatment.
Recently, advanced epigenetic sequencing and detection techniques have been developed to analyze DNA and RNA methylation (m5C, 5hmC, m6A), histone modifications (H4K16ac, H3K9me3, H3K27me3, etc.), and non-coding RNAs (miRNA, circRNA, lncRNA, ceRNA, etc.). These technologies provide valuable opportunities for identifying biomarkers that can predict drug resistance and guide the development of novel therapeutic strategies to overcome it.
By leveraging these advancements, we can enhance our understanding of the epigenetic mechanisms underlying cancer drug resistance, paving the way for more effective treatments and improved patient outcomes.
Overall, genomic epigenetic regulation significantly impacts tumor growth, metastasis, and drug resistance. Future studies are essential to deeply explore the relationship between genomic epigenetic regulation and tumor drug resistance, aiming to develop more effective strategies for cancer treatment and prevention.
We invite submissions of original research and review articles on, but not limited to, the following topics:
• Mechanisms of epigenetic regulation in drug-resistant tumors
• Influence of DNA methylation, histone modification, and non-coding RNAs on cancer drug resistance
• Epigenetic biomarkers for predicting and monitoring drug resistance
• Novel epigenetic therapies to overcome drug resistance
• Case studies and clinical trials focused on epigenetic interventions in drug-resistant cancers
Keywords: Epigenetic biomarkers, drug resistance, Epigenetic Alterations; Tumors
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
